Arthritis Pain Treatment

ACTEMRA Significantly Reduced Signs, Symptoms Of Rheumatoid Arthritis

Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs and symptoms when treated with ACTEMRA (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone. Results of the RADIATE study, which evaluated difficult-to-treat patients who failed to [...]

Posted in | Tagged | Leave a response

ACTEMRA Inhibited Progression Of Joint Damage In RA Patients Demonstrated

One-year data from a two-year Phase III study demonstrated that ACTEMRA (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen [...]

Posted in | Leave a response

Antiangiogenic Role Of 2ME2 Demonstrated In Rheumatoid Arthritis Models

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem or 2-methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School [...]

Posted in | Tagged , | Leave a response

CEL-SCI’s Rheumatoid Arthritis Vaccine Benefits Last Long

CEL-SCI Corporation presented new rheumatoid arthritis data at the 6th annual GTCbio Vaccine Conference in Vienna, Va. The data, presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology of CEL-SCI, indicate that CEL-SCI’s rheumatoid arthritis treatment vaccine CEL-2000 prevents or retards the permanent tissue damage caused by rheumatoid arthritis. The long term [...]

Posted in | Leave a response

New Clinical Practice Guideline For Knee Osteoarthritis Issued

The American Academy of Orthopaedic Surgeons (AAOS) has approved and released an evidence-based clinical practice guideline on “Treatment of Osteoarthritis of the Knee”. These guidelines were explicitly developed to include only treatments which are less invasive than knee replacement surgery. While a wide range of treatment options are available, they should always be tailored to [...]

Posted in | Leave a response

Novel Drugs May Be Hope For Rheumatoid Arthritis Treatment

Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. It enters the cell via several pathways, one of which involves folate receptor β (FRβ), which is highly specific for cells present in the joints of patients with rheumatoid arthritis (RA). During the [...]

Posted in | Tagged | Leave a response

ZARS Initiates Phase 3 Clinical Trial Of ThermoProfen For Osteoarthritis Treatment

Osteoarthritis Of Knee ZARS commenced the first of two Phase 3 clinical trials of ThermoProfen in patients with mild to moderate osteoarthritis (OA) of the knee. The Company plans to conduct two, 12-week, three arm, double blind Phase 3 efficacy trials within the United States in patients with mild to moderate OA of the knee. [...]

Posted in | Tagged | Leave a response

ACTEMRA Study Demonstrates Significant Clinical Benefit In RA Patients

Rheumatoid Arthritis Results from the AMBITION (Actemrheumatoid arthritis versus Methotrexate double-Blind Investigative Trial In mONotherheumatoid arthritispy) trial, the fourth multinational Phase III study of ACTEMrheumatoid arthritis, not only successfully met its primary endpoint of non-inferiority in patients with moderheumatoid arthritiste to severe rheumatoid arthritis, but also demonstrheumatoid arthritisted superiority over the standard effective dose regimen [...]

Posted in | Leave a response

Blacks, Hispanics More Likely To Have Disability Related To Arthritis

Among older people with arthritis, blacks and Hispanics interviewed inSpanish are more likely than whites to be unable to perform at leastone daily living activity as a result of the condition, according to astudy published in the August edition of Arthritis Care %26amp; Research, HealthDay News/Washington Post reports. For the study, researchers at Northwestern University’s [...]

Posted in | Tagged , | Leave a response

Using coxibs and NSAIDs to treat osteoarthritis

Osteoarthritis treatment In an Editorial, to be published in the international journal Osteoarthritis and Cartilage, published by Elsevier, a panel of arthritis research experts has recommended that coxibs and nonsteroidal anti-inflammatory drugs (NSAIDs) must remain a significant part of the tool kit used in osteoarthritis treatment (OA). The Editorial summarizes the outcomes of an international [...]

Posted in | Tagged | Leave a response

Interleukin Genetics Initiates Study Of Osteoarthritis Genetics

Osteoarthritis Genetics Interleukin Genetics has initiated a study on the genetics of osteoarthritis in collaboration with Dr. Steven Abramson, Director of the Division of Rheumatology at the Hospital for Joint Diseases of New York University Medical Center. Osteoarthritis (OA) is the breakdown of the cartilage cushion in one or more joints of the body leading [...]

Posted in | Leave a response

Rheumatoid Arthritis Patients To Target More Effective Treatment

Rheumatoid Arthritis More than 1,000 rheumatoid arthritis patients from West Yorkshire are to take part in a major new study which could lead to more effective targeting of treatment. A team led by Dr Ann Morgan at the Leeds Institute for Molecular Medicine in St James ,, s Hospital at the University of Leeds will [...]

Posted in | Tagged | Leave a response

Previous — Next